Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

Table 4 Prognosis according to response of neutrophil/lymphocyte ratio

Before chemotherapy > post chemotherapy	Post chemotherapy NLR < 3n = 62		Post chemotherapy NLR ≥ 3n = 39		P value
	Low > Low,n = 47	High > Low,n = 15	Low > High,n = 11	High > High,n = 28
PFS, median mo (95%CI)	7.20 (6.07-8.33)		3.47 (2.81-4.13)		0.000b
	7.60 (6.42-8.79)	5.63 (3.14-8.12)	5.77 (2.29-9.26)	3.33 (3.16-3.50)	0.000b
OS, median mo (95%CI)	10.87 (9.16-12.58)		4.47 (3.37-5.57)		0.002b
	11.4 (9.93-12.87)	8.00 (2.45-13.55)	7.63 (3.10-12.16)	7.40 (4.49-10.31)	0.001b
GA regimen	24 (51.1)	8 (53.3)	6 (54.5)	16 (57.1)	0.112
DCR	43 (91.5)	14 (93.3)	8 (72.7)	16 (57.1)	0.000b

^bP < 0.01, median (95%CI). Low, LNR < 3; high, NLR ≥ 3; Post chemotherapy, evaluation at 1^st tumor response of chemotherapy, LNR: Neutrophil/lymphocyte ratio; PFS: Progression free survival; OS: Overall survival; GA: Gemcitabine plus nab-paclitaxel; DCR: Disease control rate.